Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives

Research output: Contribution to journal › Article › Academic › peer-review

50 Citations (Scopus)

24 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	951-955
Number of pages	5
Journal	Therapeutics and Clinical Risk Management
Volume	15
DOIs	https://doi.org/10.2147/tcrm.S145630
Publication status	Published - 2019

Research programs

@article{8f6ea68ea45a491bb388c67124e18d65,

title = "Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives",

author = "Iris Overwater and Andre Rietman and {van Eeghen}, Agnies and {de Wit}, {Marie Claire}",

year = "2019",

doi = "10.2147/tcrm.S145630",

language = "Undefined/Unknown",

volume = "15",

pages = "951--955",

journal = "Therapeutics and Clinical Risk Management",

issn = "1176-6336",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives

AU - Overwater, Iris

AU - Rietman, Andre

AU - van Eeghen, Agnies

AU - de Wit, Marie Claire

PY - 2019

Y1 - 2019

U2 - 10.2147/tcrm.S145630

DO - 10.2147/tcrm.S145630

M3 - Article

SN - 1176-6336

VL - 15

SP - 951

EP - 955

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

ER -